and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.

和波士顿，2024年10月28日/PRNewswire/--AbbVie（纽约证券交易所：ABBV）和Aliada Therapeutics今天宣布了一项最终协议，根据该协议，AbbVie将收购Aliada，这是一家生物技术公司，该公司使用新型血脑屏障（BBB）交叉技术推进治疗，以解决具有挑战性的中枢神经系统（CNS）疾病。

Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer's disease..

Aliada利用这种递送技术的主要研究资产ALIA-1758是一种正在开发的用于治疗阿尔茨海默氏病的抗焦谷氨酸淀粉样β（3pE-Aβ）抗体。。

'Neuroscience is one of our key growth areas and we are committed to driving innovation in this field to address critical unmet needs for patients living with seriously debilitating neurological diseases such as Alzheimer's disease,' said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie.

艾伯维研究与发展执行副总裁兼首席科学官Roopal Thakkar医学博士说：“神经科学是我们的关键增长领域之一，我们致力于推动该领域的创新，以解决患有严重衰弱性神经疾病（如阿尔茨海默病）的患者的关键未满足需求。”。

'This acquisition immediately positions us to advance ALIA-1758, a potentially best-in-class disease-modifying therapy for Alzheimer's disease. In addition, Aliada's novel BBB-crossing technology strengthens our R&D capabilities to accelerate the development of next-generation therapies for neurological disorders and other diseases where enhanced delivery of therapeutics into the CNS is beneficial.'.

“此次收购立即使我们能够推进ALIA-1758，这是一种潜在的最好的阿尔茨海默氏病疾病缓解疗法。此外，Aliada的新型BBB交叉技术增强了我们的研发能力，以加速神经疾病和其他疾病的下一代疗法的开发，其中增强向中枢神经系统的治疗是有益的。”。

'We are pleased to announce the acquisition of Aliada by AbbVie and are excited about AbbVie's commitment to bringing ALIA-1758 to patients with Alzheimer's disease. Our proprietary MODEL™ platform has enabled the development of ALIA-1758, a promising step forward in brain delivery of an anti-amyloid antibody therapy,' said Michael Ryan, M.D., chief medical officer at Aliada Therapeutics.

“我们很高兴宣布AbbVie收购Aliada，并对AbbVie承诺将ALIA-1758带给阿尔茨海默病患者感到兴奋。Aliada Therapeutics首席医学官迈克尔·瑞安（Michael Ryan）医学博士说，我们专有的MODEL™平台使ALIA-1758的开发成为可能，这是大脑传递抗淀粉样蛋白抗体疗法的一个有希望的步骤。

'Many promising CNS-targeted therapies fail to reach late-stage trials due to their inability to cross the blood-brain barrier. Our MODEL™ platform addresses this challenge directly, efficiently delivering targeted drugs and potentially transforming how we treat neurological diseases.' .

“许多有前途的中枢神经系统靶向治疗由于无法跨越血脑屏障而未能达到晚期试验。我们的MODEL™平台直接解决了这一挑战，有效地提供了靶向药物，并可能改变我们治疗神经系统疾病的方式。”。

Aliada is advancing therapeutic candidates using its Modular Delivery (MODEL™) platform, engineered for high-precision CNS drug delivery. The novel BBB-crossing technology targets transferrin and CD98 receptors (TfR and CD98) which are highly expressed in brain endothelial cells. By engineering highly optimized TfR or CD98 binders, this platform is designed to deliver different types of biological cargoes into the brain, including therapeutic antibodies and genetic medicines such as siRNA..

Aliada正在使用其模块化递送（MODEL™）平台推进治疗候选药物，该平台专为高精度中枢神经系统药物递送而设计。新型BBB交叉技术靶向在脑内皮细胞中高度表达的转铁蛋白和CD98受体（TfR和CD98）。通过设计高度优化的TfR或CD98结合物，该平台旨在将不同类型的生物货物输送到大脑中，包括治疗性抗体和基因药物，如siRNA。。

ALIA-1758 utilizes TfR to transport a 3pE-Aβ antibody across the BBB to enable degradation and elimination of amyloid beta plaques, a pathological hallmark of Alzheimer's disease. This investigational candidate is currently in a Phase 1 clinical trial to assess its safety and tolerability in healthy participants (NCT06406348)..

ALIA-1758利用TfR通过BBB转运3pE-aβ抗体，以降解和消除淀粉样β斑块，这是阿尔茨海默病的病理标志。该研究候选人目前正在进行1期临床试验，以评估其在健康参与者中的安全性和耐受性（NCT06406348）。。

Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash, subject to certain customary adjustments. This transaction is expected to close in 4Q2024, subject to regulatory approvals and other customary closing conditions.

根据协议条款，AbbVie将以14亿美元现金收购所有未偿Aliada股权，并进行某些常规调整。该交易预计将于2024年第4季度结束，但须符合监管部门的批准和其他惯例的结束条件。

Advisors

顾问

AbbVie's legal advisor was Covington & Burling LLP. Aliada's exclusive financial advisor was Centerview Partners LLC and Fenwick & West LLP served as legal advisor.

艾伯维的法律顾问是 Covington & Burling LLP。Aliada 的独家财务顾问是 Centerview Partners LLC，法律顾问是 Fenwick & West LLP。

About AbbVie

关于AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

AbbVie的使命是发现并提供创新药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。我们致力于在几个关键治疗领域（免疫学、肿瘤学、神经科学和眼部护理）以及Allergan美学产品组合中的产品和服务，对人们的生活产生重大影响。

About Aliada Therapeutics

关于Aliada Therapeutics

Aliada Therapeutics is a biotechnology company focused on addressing delivery challenges in CNS drug development. Aliada is developing next-generation CNS therapeutics with its novel BBB-crossing Modular Delivery (MODEL™) platform technology, which has been shown to efficiently transport diverse therapeutic cargoes into the brain, enhancing effectiveness and addressing the critical need for efficient and versatile large molecule and oligonucleotide delivery.

Aliada Therapeutics是一家生物技术公司，专注于解决中枢神经系统药物开发中的交付挑战。Aliada正在利用其新型BBB交叉模块化递送（MODEL™）平台技术开发下一代中枢神经系统治疗剂，该技术已被证明可以有效地将多种治疗货物运输到大脑中，提高有效性并满足高效和多功能大分子和寡核苷酸递送的关键需求。

Johnson & Johnson (through its venture capital arm, Johnson & Johnson Innovation – JJDC, Inc.), RA Capital Management, and Raven (RA Capital Management's incubator) co-founded Aliada and co-led the series seed financing in 2021 to advance the MODEL™ platform created by Johnson & Johnson scientists that was licensed to Aliada at its inception.

强生（通过其风险投资部门，强生创新-JJDC，Inc.）、RA资本管理公司和Raven（RA资本管理公司的孵化器）共同创立了Aliada，并于2021年共同领导了系列种子融资，以推进强生科学家创建的MODEL™平台，该平台在成立之初就获得了Aliada的许可。

Further investment was made by OrbiMed and Sanofi Ventures. .

OrbiMed和赛诺菲风险投资公司进行了进一步投资。。